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VonWillebrand factor (vWF:AG) and factor VIII (VIII:C) in renal
transplant recipients under immunosuppression with cyclosporine (CsA).
B. Huser, B. Lämmle, J. Landmann, T.H. Tran, M. Oberholzer, G.
Thiel, M.J. Mihatsch, F. Duckert. Department of Internal Medicine
and Surgery and Institute of Pathology, Kantonsspital Base!, Switzer-
land. vWF:Ag levels have been proposed to be indicative for CsA-
induced vascular damage, and a high incidence of thromboembolic
complications in CsA treated kidney graft recipients may be associated
with such an endothelial damage. Determinations of vWF:Ag and
VIII:C have been performed in 17 cadaveric kidney transplant recipi-
ents immunosuppressed with CsA and steroids just before and sequen-
tially after transplantation for a period of 4 months. vWF:Ag was
quantified by Laurell electrophoresis using rabbit antihuman vWF
antibodies. VIII:C was measured by a one-stage assay using factor
Vill-deficient substrate plasma. Both proteins were elevated before
transplantation and administration of CsA:vWF:Ag 227 91% and
VIII:C 250 58% (mean so) as compared to normal human plasma.
Sequential measurements after transplantation revealed a significant
increase of mean values with highest vWF:Ag levels of 355 119% (P
<0.0001) and VIII:C levels of 390 149% (P <0.0001, Friedman test).
Despite this increase we did not observe any manifest thromboembolic
complications in our pts. Nine pts developed endothelial lesions either
due to CsA toxicity (N 6) or due to vascular rejection (N =3). The
remaining 8 pts showed a favorable outcome with good tolerance of
CsA. We found significantly lower (P < 0.01) mean values of vWF:Ag
in pts developing endothelial cell damage (n = 9) compared to pts with
favorable outcome (N = 8, mean peak values SD = 299 118% vs.
436 62%, respectively). However, this was already the case before
transplantation (176 37% vs. 285 102%, P < 0.01). Concerning
VIII:C there was no difference between the two groups. We found no
correlation between vWF:Ag and VIII:C on the one hand and CsA dose
(mg/kg), CsA blood levels and plasma creatinine on the other hand. In
conclusion, our results are in contrast to recent reports suggesting an
indicative value of vWF:Ag determinations concerning outcome of graft
in kidney transplant recipients treated with CsA.
Prognosis of glomerulonephritis in children. B. Knittel, R. Kie/stein,
L. Lachhein, Medizinische Akademie Magdeburg, German Democratic
Republic. Acute symptoms often herald the onset of glomerulonephritis
(GN) in children, making it easier to determine the time course and risk
of developing renal insufficiency than in adults. From 1967 to 1985
biopsies were taken from 100 children (6 to 16 years) suffering from GN.
These biopsies confirmed most of the cases (72%) as mesangioprolifei--
ative, 8% IgA and 8% with minimal changes. Fifteen children with such
syndromes as Henoch-Schoenlein, HUS, or Alport's were classified
according to WHO criteria. Symptoms of the nephrotic syndrome and
of hypertension were treated. In 1987 eighty-one of the study patients
were again examined with clinical and laboratory methods. Of these, 30
children (37%) had normal serum creatinine (SCr) and urine analyses on
repeated follow-up examinations. Twenty-three patients (28%) had
elevations of Sr and/or hypertension. Another 23 patients (28%) 50
examined showed significant proteinuria. Five patients (6%) required
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maintenance dialysis. After up to 20 years of observation the onset of
renal insufficiency (Sc 120 smol/liter) and terminal renal failure (Se.
900 tmol/liter) was calculated cumulatively at 37% and 18%, respec-
tively. This incidence of the risk of uremia is similiar to our earlier study
of 308 adults. Prognosis and effectiveness of therapy is provable only
through studies of long duration. Our two examinations emphasize that
uremia also in mild forms of GN is more frequent than until now has
been considered.
Cyclosporin A monotherapy after kidney transplantation. M. Tamm,
B. Huser, F. Brunner, M. Mihatsch, J. Landmann, G. Thiel, Departe-
ment Innere Medizin, Chirurgie und Pathologie, Kantonsspital Base!,
Switzerland. Ninety-nine of 171 patients who received a first kidney
transplant between 1983 and 1987 were placed on immunosuppression
with cyclosporin A only within 4 to 6 months. Fifty-five patients could
be maintained on a cyclosporin A monotherapy indefinitely. For 44
patients this goal could not be achieved. In this group the mean value
creatinine rose from 143 to 193 rmol/liter. In 33 biopsies of the
transplant we found a rejection II times and a rejection combined with
cyclosporin A toxicity 13 times; in 9 cases there was only cyclosporin
A toxicity. If steroids were added or the therapy was changed to
azathioprine the renal function improved in most patients. In 7 patients
the last creatinine was more than 200 smol/liter, 2 of them showed an
increasing renal dysfunction. No difference could be shown between
the two groups regarding the age, diagnosis, cyclosporin A dose,
cyclosporin A level, HLA matching and percentage of cytotoxic
antibodies. Conclusions: 1)43% of all patients with a functioning kidney
transplant could be maintained on cyclosporin A monotherapy indefi-
nitely. 2) None of the factors examined could predict the success of a
cyclosporin A monotherapy. 3) Only 2 of the 99 patients showed a
progressive renal dysfunction which was probably caused by the
cyclosporin A monotherapy.
Acute renal failure after repeated joint irrigation with Neomycin/
Bacitracin containing solutions. M. Schmidli, F. W. Reutter, Medizinis-
che K/inik B, Kantonsspital, CH 9007 St. Gal/en, Switzerland. Two
patients who developed acute reversible renal failure after local drain-
age and irrigation with Neomycin/Bacitracin solution containing 330 mg
Neomycin and 25'OOO LE Bacitracin in l'OOO ml of 0,9% sodium chloride
are described. Case 1: A 70-year-old female after synovectomy and
cartilage-shaving for acute pyogenous gonarthritis due to staph. aureus
was treated for 4 days with the above described local irrigation
drainage. She retained approximately 450 to 1,090 ml of the irrigation
solution daily, leading to Neomycin resorption of approximately 1,060
mg or 3.5 mg/kg body wt per day. On the 15th postoperative day
nonoliguric renal failure with serum creatinine of 737 smol/liter and
Clcr of 5 mI/mm developed. BP 160/80mm Hg, urine analysis wnl. One
treatment with hemodialysis was followed by spontanous recovery of
renal function. Neomycin induced nerve deafness developed within a
month. Case 2: A 78-year-old female was treated with irrigation-
drainage of the right knee-joint because of bacterial gonarthritis with the
above mentioned fluid, of which approximately 500 ml were retained
daily leading to resorption of 1,480 mg Neomycin or approximately 2.5
mg/kg body wt per day. After 10 days creatinine was 447 mol/liter,
creatinine clearance 6 mI/mm, proteinuria 0.3 g/24 hr and glycosuria 2.8
mmol/liter at normal blood glucose. Renal biopsy showed typical toxic
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alterations of the tubular epithelium. Renal function normalized within
10 days after stopping the joint irrigation. Discussion: Toxic tubular
damage due to high serum aminoglycoside concentrations after local
joint irrigation is the most likely cause of renal failure in the two
presented cases. Resorption of locally applied Neomycin is known for
the peritoneum. In the two cases synovial inflammation might have
enhanced antibiotic resorption. Joint irrigation with Neomycin solu-
tions for more than 4 days can, especially if drainage is delayed, cause
considerable Neomycin resorption resulting in nephro- and ototoxicity.
Renal scarring and course of vesicoureteric reflux (VUR) in infants and
children. N. Barakat, U. Willi, E. Leumann, Universitäts-Kinderklinik,
Steinwiessir. 75, 8032 Zurich, Switzerland. VUR is a well known
condition for ascending renal infection and subsequent scar formation.
Whether treatment should be surgical or conservative remains debated.
The notes of 1225 children who underwent uroradiological evaluation
between 1982 and 1987 were available for review. Of these, 487
exhibited VUR at their first examination, and 296 were followed-up at
our institution. Sixteen were excluded from the study because of
associated anomalies. Of the remaining 280 children included in the
study, 82 were primarily operated for VUR, and 198 were treated
conservatively. Below the age of 1 year there were more boys (56%);
above 1 year of age, girls predominated (75%). Bilateral VUR was
observed in 56% of children. Of the 421 refluxing ureters, VUR was
grade I in 9%, II in 38%, III in 39%, IV in 10%, and V in 4%. Among the
198 conservatively treated children with renal scarring, 12% were below
the age of 1 year, and 28% were above. The first follow-up examination
was done at an average interval of one year. Of 110 initially grade III
refluxing ureters, VUR disappeared in 20%, became less in 31%, and
remained unchanged in 47%. In 2% VUR increased. Disappearance of
VUR was seen in 31% of infants and 11% of children> 1 year of age.
Of 138 initially grade II refluxing ureters, VUR disappeared in 36%,
became less in 15%, and remained unchanged in 45%. In 4% VUR
increased. Disappearance of VUR was observed in 50% of infants and
25% of children> 1 year of age. Conclusions: 1) referral of children for
uroradiological evaluation should not be delayed since renal damage
increases with age, 2) the younger the child, the higher is the tendency
for spontaneous resolution of VUR.
Complement activation by the alternative pathway is modified in renal
failure: The role of factor D. M. Pascual, .1-P. Paccaud, K. Macon, J.E.
Volanakis, J.A. Schfferli, Departments of Medicine, Hôpital Cantonal
Universitaire, Geneva, Switzerland, and University of Alabama, Bir-
mingham, USA. Factor D is an essential enzyme of the alternative
pathway (AP) of complement. Factor D is eliminated by the kidney, and
its plasma concentration increases 10-fold in end-stage renal failure
(ESRF). The purpose of this study was to analyze the consequences of
factor D accumulation. Different in vitro assays were used to analyze
AP activation in normal human serum (NHS), in normal serum supple-
mented with purified factor D to 10-fold its normal concentration (10 x
D), and in sera of patients with ESRF. When compared to NHS, in 10
x D: (I) spontaneous fluid-phase activation of complement at 37°C was
greatly increased as measured by C3 cleavage; (2) the lysis of rabbit
erythrocytes, a function of the AP, was accelerated; (3) more radiola-
belIed C3 fragments bound to cuprophane membranes and to immune
precipitates, reactions that were accompanied by the formation of more
C5a; (4) Complement mediated solubilization of antigen-antibody pre-
cipitates was enhanced. When compared to normal sera, sera of
patients with ESRD behaved similarly to 10 x D in all assays used, that
is, enhanced complement activation by the AP, although complement
activation measured in these assays varied widely from one individual
to another in both groups. Thus the elevated factor D concentration
observed in renal failure might have important pathophysiological
consequences, some of which being detrimental (such as, C5a produced
during hemodialysis), but others might be beneficial (solubilization of
immune precipitates).
The value of sonography in the diagnosis of kidney disease. J. Tuma,
Internistische Praxis, 8610 Uster, Switzerland. The evaluation of diag-
nostic ultrasound in nephrology is based on over 7000 performed
examinations. While until some years ago renal sonography was at most
acknowledged to be useful in measuring kidney size, several nephrol-
ogists today have seen the ample advantages of this diagnostic proce-
dure and perform the examinations themselves. For several years
sonography has been an approved diagnostic method for renal cysts,
renal tumors and polycystic kidney disease. Furthermore, sonomorpho-
logic findings in small kidneys may give additional information about
the underlying disease (chronic pyelonephritis, renal artery stenosis,
benign nephrosclerosis or analgetics-nephropathy). Larger vascular and
pyelonephritic scars are well discernible. Diagnosis of hydronephrosis
yields a high sensitivity; similar sonomorphologic findings, however,
may lead to confusion, such as megacaliosis, multiple parapelvic cysts
and dystopic kidneys. Calculi in the urethra as the most common cause
of hydronephrosis are demonstrable in 89% of the cases. In acute
parenchymal kidney disease a nonspecific echo enhancement of the
renal cortex is usually seen, correlating with the severity of functional
impairment. Newer sonographic techniques, duplex and color coded
scanning, are so far used in the diagnosis of tumors, artery stenosis and
transplant rejection; other indications are under investigation. The
non-invasive character of the procedure, the lack of radiation exposure
and the diagnostic precision are reasons for considering sonography of
the kidneys as basic diagnostic tool besides the classic urine sediment.
Fleroxacin metabolism in patients with renal failure. A.E. Stuck, E.
Weidekamm, P. Heizmann, F.J. Frey, Medizinische Polik/inik, Insel-
spital, CH-3010 Bern, Switzerland. Fleroxacin is a quinolone derivative
with a broad in vitro antibacterial activity, including staphylococci, and
may be used in patients with impaired renal function or as a therapeutic
agent in CAPD-related peritonitis. Therefore, we investigated the
metabolism of fleroxacin after i.v. (100 mg) and p.o. (400 mg) dosing in
26 subjects with varying renal function, including 7 patients on CAPD.
The volume of distribution, the systemic availability and the peak
concentration after the administration of oral fleroxacin were indepen-
dent of the GFR. As a consequence of a declining renal clearance, the
total body clearance of fleroxacin declined with decreasing GFR from
1.41 0.23 mI/mm/kg in subjects with normal renal function to 0.58
0.13 mI/mm/kg in patients with end-stage renal disease (r = 0.84, P <
0.001). The N-oxide metabolite exhibited formation-limited and the
N-demethyl metabolite elimination-limited kinetics. The mean dialy-
sate/plasma equilibration ratio of fleroxacin ranged from 0.52 to 0.71 in
patients on CAPD, resulting in a 7.8 3.6% recovery of unchanged
fleroxacin in peritoneal dialysate. We conclude that: (1) a 50% reduction
of the maintenance dose can be recommended in patients with a GFR
below 20 to 30 ml/min/l .73 m2; and (2) therapeutic concentrations of
fleroxacin in the peritoneal fluid may be achievable after oral adminis-
tration in patients on CAPD.
Efficacy and pharmacokinetics of piretanide in patients with congestive
heart failure. C. Marone, B. Rivera, H. Zwahlen, F. Frey, Ospedale
San Giovanni, Bellinzona and Medizinische Universitäts-Poliklinik,
Berne, Switzerland. The efficacy and pharmacokinetics of the loop
diuretic piretanide were studied in two groups of 6 hospitalized patients
with congestive heart failure. In the first group a dosage of 2 x 6 mg/day
to 2 12 mg/day of piretanide was given intravenously during 7 days.
This was sufficient to abolish the different signs and symptoms of
cardiac failure such as dyspnea on exertion, orthopnea, pulmonary
rales, neck vein distension and peripheral edema and to reduce cardiac
enlargement. Six mg of intravenous piretanide were then given to the
second group of patients with congestive heart failure in order to study
its pharmacokinetics. When compared with healthy volunteers, these
patients had a reduced total body clearance of about 50% which was
attributable to a diminished renal but not nonrenal clearance. The
analysis of the interrelationship between urinary piretanide excretion
and diuresis by means of a linearized EmaxmOdel revealed a maximal
diuresis of 252 mI/hr and an urinary piretanide excretion to induce
half-maximal diuresis of 229 pg/hr. Thus patients with congestive heart
failure exhibit a decreased renal clearance of piretanide and a good
response to this high-ceiling diuretic after intravenous dosing.
Making glomerular red cells by filtration: Roles of pH and osmolality.
V. Briner, W.H. Reinhart, Medizinische Universitdtsklinik, Inseispital,
CH-3010 Bern, Switzerland. Distorted red blood cells (RBCs) in the
urine have been recognized as a good indicator of glomerular bleeding.
It is still not clear how these glomerular RBC shapes develop. It has
been suggested that mechanical stress, urinary pH, and osmolality may
play a role. We have investigated these factors systematically. Whole
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blood (10 ,.d) anticoagulated with EDTA was added to fresh urine (5 ml)
from healthy volunteers. This suspension was filtered with a constant
flow rate (0.5 mI/mm) through polycarbonate filters with pore diameters
of 3 tm. The filtrates were incubated at 37°C for I hr, centrifuged, the
sediment fixed with 1% glutaraldehyde, and examined with phase-
contrast microscopy. The pH of the urine was altered with NaOH or
HCI (pH range 5—8), the osmolality by adding H20 or NaCI (range 200
to 900 mOsm/g). It was found that: a) glomerular RBCs can easily be
produced by this filtration technique; b) certain glomerular shapes
occurred at specific conditions, such as echinocytic RBCs at high pH
and high osmolality, RBCs with prominent spherical protrusions ("sat-
ellites") at low pH and high osmolality, irregular small remnants of
RBCs at low pH and low osmolality, doughnut-shaped RBCs at
osmolality around 300 mOsm/kg; C) hemolysis increased with decreas-
ing osmolality independent of pH. Urine from two patients with
glomerulonephritis yielded similar results. When phosphate buffered
saline was used instead of urine, no glomerular RBCs could be
produced within a range of pH 6 to 8 and 300 to 500 mOsm/kg; outside
this range glomerular RBCs occurred. We conclude that the formation
of glomerular RBCs can be reproduced in vitro and that mechanical
factors such as the passage of a narrow pore, the osmolality, the pH,
and urinary substances not yet identified play a role and can determine
the type of morphological abnormality. Falsely negative results of
urinary RBC examination in glomerulonephritis may be caused by
unfavorable urinary pH and osmolality.
Genetic risk of hypertension in glomerulonephritis. M. Schmid, S.
Meyer, R. Wegner, E. Ritz, Department Internal Medicine, Heidelberg,
Federal Republic of Germany. The interrelation between hypertension
and glomerulonephritis (GN) is complex. We examined the genetic risk
of hypertension in biopsy-confirmed primary chronic glomerulonephri-
tis. Sixty-four parents of 40 patients consecutively admitted with
biopsy-confirmed primary chronic GN (excluding hereditary GN of
Alport type by EM) were examined. Of the patients' parents, 68.7%
were hypertensive (48% on antihypertensive medication, 20% elevated
BP, WHO criteria, on examination). In 109 parents of 70 age- and
sex-matched controls, that is, patients admitted to a surgical ward for
minor trauma, hypertension was found in 33% (18% on antihyperten-
sive medication, 15% elevated BP on examination). In 24 patients and
19 controls, both parents were alive. Hypertension in both parents was
found in 50% of GN and 7.7% of control patients. A similar proportion
of parents of GN patients or controls had died. There was similar
cardiovascular and no renal mortality in either group. Blood pressure
status in parents predicted blood pressure in offspring. Microscopic
hematuria and/or proteinuria was found in a similar proportion of the
parents of patients with GN or controls respectively. Parents were
comparable with respect to age, sex ratio and body mass index. We
conclude that the genetic risk of hypertension is increased in patients
with primary GN. Several potential mechanisms may explain a causal
relationship between and/or association of hypertension and glomeru-
lonephritis.
Influence of apical medium pH on tetraethylammonium transport
across monolayers of a renal epithelial cell line (LLC-PK1). A. Fouda, C.
Fauth, F. Roch-Ramel, Institut de Pharmacologie de 1' Université de
Lausanne, CH-1005 Lausanne, Switzerland. To characterize the mech-
anisms implicated in the basolateral to apical (b—a) transport of
tetraethylammonium (TEA), LLC-PK1 cells were grown on collagen-
coated Nucleopore filters attached to Transwell, which allow free
access to apical and basolateral compartments separately. Unidirec-
tional transepithelial (J b—*a) fluxes of '4C-TEA (J b_*aT) and
3H-mannitol (J ba'1) (an extracellular marker) were measured
simultaneously across LLC-PK1 monolayers (pmol/[cm2 . 2 minI), with
basolateral medium substrate concentrations of 9 M. After a 2-minute
flux measurement, the cell monolayers were rapidly detached from the
Transwell and '4C-TEA and 3H-mannitol radioactivity linked to the
cells counted to calculate intracellular 4C-TEA concentration (pmol/g
DNA). At basolateral and apical pH medium of 7.4, J b_*aT was 54.5
4.0 (N = 6) and '4C-TEA cell concentration 4.8 0.1. Acidification
of apical medium to pH = 6.0 stimulated J b.*aT to 84.5 7.5 (N =
5), and decreased intracellular "C-TEA concentration to 1.6 0.2, J
b*ammt0I was not influenced by changes in medium pH (pH'° =
7.4: 1.5 0.2 versus pH°"' = 6.0: 1.6 0.2). These observations
demonstrate that the organic cation-proton exchanger which was char-
acterized in apical membranes vesicles of proximal tubular cells plays a
role in the TEA transepithelial transport in intact epithelial cells.
Reduced inhibition of calcium oxalate monohydrate (COM) crystal
aggregation in vitro by nephrocalcin (NC) isolated from stone former
urines and from human kidney stones. B. Hess, Y. Nakagawa, F.L. Coe,
Medizinische Klinik, Universitätsspital Zurich, Switzerland, and
Nephrology Program, University of Chicago, Chicago, USA. NC
isolated from urines of recurrent calcium kidney stone formers (sf NC)
and from human calcium oxalate kidney stones (stone NC) lacks
y-carboxyglutamic acid and exhibits weak surfactant properties com-
pared to normal urinary NC (n NC), a 14 kD glycoprotein. These
structural deficiencies go along with a reduced inhibition of COM
crystal growth in vitro only by sf NC, but not by stone NC, whose
affinity to the COM crystal surface is as high as the affinity of n NC. We
studied the influence of all three NCs on the aggregation of COM
crystals in vitro, because crystal aggregation is the more dangerous step
in the formation of large crystalline particles in renal tubules. Aggrega-
tion was induced at 37°C by slow stirring (500 rpm) of an equilibrated
COM crystal slurry at pH 7.2 and ionic strength of 0.10. Rate of
aggregation was measured spectrophotometrically during spontaneous
particle sedimentation by the rate of decrease of turbidity at 620 nm that
reflects terminal particle velocity and, therefore, particle size. Electro-
static surface charge of COM crystals (Zeta potential, ZP), a basic force
of particle repulsion, was calculated from the electrophoretic mobility
of the crystals, measured by a Zeta Meter. Inhibition of COM crystal
aggregation increased with increasing NC concentration; at 2 x l0 at,
inhibition by n NC was 90%, but only 32% by either sf NC or stone NC.
The ZP of control COM crystals without NC was + 13.8 mV; incuba-
tion with all forms of NC induced a negative ZP, indicating binding of
NC to the crystal surface. At all NC concentrations studied, ZP was
more negative for n NC than for sf NC and stone NC, respectively (P
< 0.001). The negativity of ZP did not increase with increasing
concentrations of all forms of NC, although crystal aggregation inhibi-
tion increased. Conclusions: Compared to n NC, sf NC and stone NC
are structurally and functionally defective COM crystal aggregation
inhibitors. Since increasing COM crystal aggregation inhibition with
increasing NC concentrations is not related to more negative ZPs, the
negative electrostatic surface charge induced by NCs binding to COM
crystals does not seem to be important for efficient inhibition of COM
crystal aggregation in vitro.
Fibrobtasts may represent the main site of production of interstitial
adenosine in the kidney. M. Le Hir, B. Kaissling, R. Gandi, U.C.
Dubach, Medizinische Universit/its-Poliklinik, Kantonspital, and Anat-
omisches institut, Base!, Switzerland. Adenosine plays a role in the
regulation of renal hemodynamics, of GFR, of tubular transports and of
the release of renin and possibly of erythropoietin. Adenosine origi-
nates from the hydrolysis of 5'-AMP by 5'-nucleotidase (5'-Nu). We
found two 5'-Nu in the rat kidney. One, which is presumably cytosolic,
shows a much higher affinity for 5'-IMP than for 5-AMP. Thus it
produces inosine rather than adenosine. The second, a membrane-
bound 5'-Nu, has the reverse specificity. As an ecto-enzyme it produces
adenosine directly into the extracellular space. Using specific inhibi-
tors, Ramos-Salazar and Baines proved the importance of this enzyme
for the production of adenosine during renal hypoxia. We localized the
ecto-5'-Nu in the kidney by enzyme histochemistry and immunohisto-
chemistry. The ecto-5'-Nu is present in the brush border of the
proximal tubule, in the intercalated cells and in the fibroblasts of the
cortical labyrinth. Fibroblasts in the medullary rays and in the medulla
were almost or completely negative. Ecto 5'-Nu was not detected in the
endothelium or in other compartments of the walls of blood vessels.
The adenosine which is produced at the luminal aspect of epithelial cell
by ecto-5'-Nu can be lost in urine or taken up in the epithelial cells. In
the latter case adenosine is very rapidly desaminated to inosine, as
shown in our previous studies with brush border vesicles. On the
contrary, adenosine produced by fibroblasts would have direct access
to important targets, namely the walls of arteries and arterioles, the
nerve endings along vessels and tubules, and possibly the erythropoi-
etin-producing cell. It is noteworthy that the most conspicuous accu-
mulation of 5'-Nu-positive fibroblasts is in the vicinity of the arteries
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and arterioles, around which they often constituted a continuous layer.
The erythropoietin-producing cells have not yet been identified, but like
the 5'-Nu-positive fibroblasts they are localized in the peritubular space
of the cortical labyrinth. Under conditions of energy deficit, such as in
hypoxia, the concentration of 5'-AMP in tubular cells rises. We
hypothesize that as a consequence of this the release of 5'-AMP by
these cells into the peritubular space may increase. Through the action
of 5'-Nu of fibroblasts, this could result in an enhanced interstitial
concentration of adenosine.
A signal transduction in the kidney through the release of phosphati-
dylinositol-anchored brush border proteins? M. Le Hir, G. Piec, U.C.
Dubach, Medizinische Universitars-Poliklinik, Kantonspital, 4031
Base!, Switzerland. It has been recently recognized that many proteins
are anchored at the outer face of the cell membrane by covalent binding
to phosphatidyl inositol (P1) instead of having an hydrophobic peptide
sequence embedded in the lipid bilayer. The ecto-5 -nucleotidase (5-
Nu) and alkaline phosphatase (Al-Pase) of the brush border membrane
of the renal proximal tubule belong to their group. A proposed role of
that type of anchor lies in the production of signal substances in the
membrane. For instance the hydrolysis of the anchor by phospholipases
yields phosphatidic acid or diacylglycerol while the protein is released
in a soluble form, Solubilization of P1-anchored ecto-enzymes within a
few minutes of specific simulation has been reported in a few cell types.
We found in the rat kidney soluble forms of 5'-Nu and of Al-Pase. Their
molecular weights are indistinguishable by gel filtration from those of
5'-Nu and Al-Pase released in vitro from renal membranes by phospho-
lipase C. The soluble 5'-Nu was inhibited by antibodies raised against
the purified membrane-bound 5'-Nu. This suggests that the soluble
forms found in the kidney originate from the membrane-bound enzymes
by hydrolysis of their Pt anchor. The soluble activities of 5-Nu and of
Al-Pase in the kidney nearly doubled within 10 mm under three
circumstances: 1) after clamping the contralateral renal artery, 2) after
ligature of the ureter, 3) during the infusion of ANF. Denervation of the
artery prior to its clamping abolished the solubilization of the two
enzymes. Leucine aminopeptidase, an ecto-enzyme of the brush border
which is anchored to the membrane by an hydrophobic domain of the
polypeptide, was not solubilized by these maneuvers. This suggests that
the solubilization is due to a specific hydrolysis of the P1 anchor. We
propose that some, still to be defined, stimuli provoke the activation of
an anchor-specific phospholipase in the proximal tubule. This would
release P1-anchored proteins and leave in the membrane molecules with
established signal functions.
Protective effects of phenoxybenzamine in experimental iscbemic acute
renal failure. S.G. Shaw, P. Weidmann, A. Zimmermann, Medizinische
Poliklinik und Pathologisches Institut, Universität Bern, Switzerland.
Previously we have found that in the early phase of ischemic acute renal
failure (ARF) produced by 45 to 60 mm of bilateral renal artery
clamping (RAC) in the rat, renal tissue and circulating catecholamines
(CA) are increased and may partly contribute to the loss of renal
function. To examine whether CA a-receptor mechanisms may be
involved, potential beneficial effects of pre-treatment with the irrevers-
ible CA a-receptor blocking agent phenoxybenzamine (PB, 2 mg/kg iv.
3 hr before RAC) were investigated in Sprague-Dawley rats under
nembutal anaesthesia 24 hr after 45 mm of RAC. Clearance of C 14
inulin (GFR), urine flow (Uv), fractional excretion of sodium (FENa),
mean arterial pressure (MAP), free water clearance (CH,o), plasma
creatinine (Per) and histology were assessed. (results SCM, P < 0.05
compared to control, N = 8).
Normal
24 hr after 45 mm of RAC
PB treated Control
GFR ml/min/100 g 0.85 0.07 0.3 0.0l 0.12 0.01
FENa% 0.18 0.05 2.0 0.4a 11.2 4
CH mi/hr
MAPmmHg
—2.7 0.2
120±5
—0.8 0.Ia
118±2
—0.38 0.1
115±2
Uv mi/hr 0.6 0.1 2.1 Ø,4 2.9 0.6
Pmg/dl 0.55 1.3 0.l2 2.3 0.17
Histologically, PB treated animals showed a lesser degree of residual
hyperemia in the renal medulla compared to non-treated controls.
These findings demonstrate that PB attenuates the severity of renal
impairment induced by 45 mm of RAC and provides additional evidence
implicating CA mechanisms in the pathogenesis of ARF.
Electromagnetic measurement of vibratory thresholds in chronic renal
failure. M.J. Hilz, D. Claus, B. Neundorfer, B. Schulig, 1. Braun,
Neuro!ogische und Nephrologische, K!inik der Universität Eriangen-
Nurnberg, Federal Republic of Germany. In chronic renal failure,
clearly defined parameters to ascertain the necessity of further hemo-
dialysis are rare. Impairment of nerve conduction velocity (NCV) has
sometimes been suggested as an indicator for dialysis to be repeated.
Electromagnetic measurement of vibratory thresholds (VT) also reveals
dysfunction of thickly myelinated (A-beta-) nerve fibres. We asked
whether VT measurement—executed by a Somedic AB vibrameter—
correlates with NCV strongly enough to partially replace or complete
NCV measurement, and also to follow the development of neuropathy.
In 80 patients suffering from chronic renal failure, clinical neurological
status, NCVs of median, tibial, peroneal, and sural nerve, and VTs at
both medial malleoli were examined. Forty patients (group A) had been
hemodialyzed for less then 3 months. Forty patients (group B) had
already been undergoing dialysis for more than 2-1/2 years. The two
groups were compared to see whether VT measurement is useful for
early diagnosis and observation of the development of nephrogenic
neuropathy, Clinical symptoms and signs of neuropathy were found in
10 patients of group A and 17 patients of group B. Statistically, the
difference was not significant. In contract, incidence of impaired NCV
showed a significant progression from group A (18 patients) to group B
(30 patients) ( = 6.302; P < 0.05). In addition, mean values of NCV
were slightly lower in group B than in group A (U-test: P < 0.05).
However, incidence of raised VTs did not differ significantly in either
group (A: 19 patients—B: 22 patients). Conclusion: In uremic patients,
VT measurement reveals lesions of myelinated fibres (47.5%) as often
as NCV does (45%). It is more specific than mere clinical examination.
It widens applied diagnostics to observe the development of nephro-
genic neuropathy. It might partially substitute for NCV measurement.
Transport of methotrexate (MTX) by the in vitro isolated rabbit
proximal tubule (PT). K. Besseghir, D. Mosig, F. Roch-Ramel, Institut
de Pharmacologie, CH-1005 Lausanne, Switzerland. Nephrotoxicity
represents a potentially fatal drawback during high-dose therapy with
the antifolate MIX, a drug which is eliminated mainly via the renal
route. The tubular mechanisms underlying this renal excretion were
investigated using the isolated rabbit PT. In nonperfused tubules bathed
in a medium containing 3H-MTX, MTX accumulation was observed to
be highest in the S2 segment, intermediate in the S1 and lowest in the S3
part of the PT (tubular/medium concentration ratio of 8.2 1.0, 6.8
1.6, and 5.2 0.8, respectively, N = 5 to 8). A comparable distribution
was observed for MTX secretion in the perfused PT: secretion was (in
fmol/mm mm) 0.25 0.07 (N = 5), 0.45 0.13 (N = 10) and 0.14
0.04 for the S1. S2 and S3 segments, respectively (bath [MTX] = 0.4
SM). In the S2 segment, this secretion could be inhibited by folate and
by the organic anion transport inhibitor probenecid (both at 500 tM).
Saturation studies indicated that both the efficiency of MIX transport
and MIX apparent affinity for its transporter were low (478 48
fmol/mm mm and 363 32 M, respectively), explaining that secre-
tion against a concentration gradient could be observed only at very low
flow rates. High performance liquid chromatography of the label
associated with MIX indicated a certain extent of metabolism into an
unknown compound during secretion. Tubular reabsorption repre-
sented less than 5% of perfused MIX, and appeared only of passive
nature. MTX renal transport appears thus represented mainly by a
relatively inefficient PT secretion mediated by the organic anion sys-
tem, occurring mostly in the S2 part of the PT, and eventually
accompanied by local metabolism.
Regulation of erythropoietin production is related to proximal tubular
function. K.- LI. Eckardt, A Kurtz, C. Bauer, Physiologisches Institut,
Unh'ersität Zurich, CH-8057 ZOrich, Switzerland. Regulation of renal
erythropoietin (EPO) production is based on an intrarenal oxygen
sensor. While the sensitivity of this oxygen sensor to variations in renal
oxygen supply is well established, the influence of changes in renal
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oxygen consumption has not yet been elucidated. Diuretic drugs, that
inhibit active sodium reabsorption, reduce tubular oxygen consump-
tion. We therefore investigated the effects of acetazolamide, furo-
semide, hydrochlorothiazide and amiloride, known to inhibit sodium
reabsorption at different segments of the nephron, on hypoxia induced
EPO formation in mice. We found that effective inhibition of sodium
reabsorption in the loop of Henle (furosemide), distal tubule (hydro-
chlorothiazide and amiloride) and collecting duct (amiloride) did not
blunt EPO production. Inhibition of proximal tubular sodium reabsorp-
tion with acetazolamide on the other hand significantly reduced EPO
formation in response to normobaric arterial hypoxia (8% and 14% 02)
and functional anemia (0.1% carbon monoxide). This inhibitory effect of
acetazolamide was dose dependent and correlated with the natriuresis
induced. It appeared not to be related to the metabolic acidosis induced
by the drug, since the simultaneous administration of sodium bicarbon-
ate, which restored standard bicarbonate levels to normal, did not
diminish the inhibitory effect on EPO production. We conclude that the
regulation of EPO production is linked to reabsorptive function of the
proximal tubule and is independent of tubular function in more distal
segments of the nephron.
Multiple site estimates of plasma erythropoietin and renin in poly-
cythemic patients after kidney transplantation. Preliminary results. f.M.
Aeberhard, P.A. Schneider, A. Kurtz, M.B. Vallotton, M. Leski,
Départements de Medecine and Radiologie, Hôpital Cantonal Uni-
versitaire, Genève et Physiologisches Institul, Universität Zurich,
Switzerland. We tried to demonstrate an abnormally increased eryth-
ropoietin (EPO) production by the patients' native kidneys when
polycythemic after renal transplantation. Six male patients with 6 to 26
months elapsed since transplantation were studied. Three of them were
polycythemic(hematocrit 55 to 53, 5 1.5%, and hemoglobin 18.6 to 17.5,
17.2 g/100 ml). In the remaining three without polycythemia a refractory
hypertension led us to perform a multiple-site plasma renin estimation.
Samples were obtained by means of selective venous catheterization of
the native kidneys (NK), of renal graft (RG) and inferior vena cava
(IVC); erythropoietin and renin estimations were performed in each
sample by radioimmnoassay. Results: peripheral EPO levels in the
three polycythemic patients were higher than in the three others and
normals. The NK/IVC ratio was more than 2.15 in polycythemics, less
than 1.36 in the three other cases. RG/IVC ratio was always beneath
1.35. There was no correlation between plasma levels of EPO and renin.
Preliminary conclusions: in kidney transplanted patients, immunosup-
pressed by cyclosporine, polycythemia seems related to an abnormal
increase of EPO release by the native kidneys. In these shrunken
kidneys EPO and renin production seem to be independent from each
other.
Calcium antagonists augment the cyclosporin A induced inhibition of
T.cell proliferation. M. Marx, H. Dumann, M. Weber, K.-H. Meyer
zum Buschenfelde, H. Kohler, 1. Medizinische Klinik and Poliklinik der
Universitat Mainz, Federal Republic of Germany. Calcium antagonists
are known to modify the distribution of renal perfusion and to interfere
with the metabolism of cyclosporin A (CsA). Their application may
favourably influence the survival of renal allografts. Moreover, calcium
antagonists exert an own immunosuppressive effect by blocking T-cell
mitogenesis. On the other hand CsA inhibits the T-cell proliferation by
blocking a calcium-dependent signal. It was the aim of this study to
investigate a possible additive effect of calcium channel blocking agents
on the CsA induced inhibition of T-cell proliferation. Peripheral blood
lymphocytes and T-cells were isolated using standard methods and
cultured in the presence of 0.5 tg/ml phytohemagglutinin (PHA). CsA
(0.025 to 10 gIml), verapamil (Ver; 0.3 to 40 .rg/ml), nifedipine (Nif;
0.39 to 25 .tg/ml) or nimodipine (Nim; 0.39 to 25 tg/ml) were added to
the cultures, either alone or in combination. The cultures were termi-
nated after 96 hours and 3H-thymidine uptake was measured to estimate
the proliferative response. Dose response curves for all substances or
their combinations were constructed. A 50% inhibition of T-cell prolif-
eration was achieved with 500 ng/ml CsA, 10 rg/ml Ver, 6.25 pg/mI Nif,
and 1.56 pg/mI Nim, compared to controls with PHA alone. A further
significant decrease of T-cell proliferation was obtained, when calcium
antagonists and CsA were combined in doses, where each drug alone
demonstrated a 50% inhibition: CsA + Ver to 31%, CsA + Nif to 15%
and CsA + Nim to 18%. Moreover, a substantial inhibition of T-cell
proliferation was also obtained, when CsA (125 ng/ml) and calcium
antagonists were combined in low concentrations. In these concentra-
tions the drugs alone induced only minor or even no antiproliferative
responses, whereas their combinations induced the following inhibi-
tions: CsA + Ver (2.5 pg/mI) to 46%, CsA + Nif (1.5 j.tg/ml) to 50% and
CsA + Nim (0.39 pg/mI) to 46%. Calcium channel blocking agents exert
a dose dependent inhibition on lectin-stimulated T-cell proliferation. A
combination of CsA and calcium antagonists is more effective than each
drug given alone. Moreover, a substantial antiproliferative effect could
be demonstrated even in doses, where CsA or calcium antagonists
alone show only minor or no effects. This synergistic effect of calcium
antagonists and CsA may result in a better graft survival and possibly
help to reduce the CsA induced nephrotoxicity.
Evidence for inherited structural and functional abnormalities of
Tamm-Horsfall glycoprotein (THP) among patients with idiopathic cal-
cium oxalate nephrolithiasis. B. Hess, Y.Nakagawa, F.L. Coe, Mediz-
inische Klinik, Universitiitsspital Zurich, Switzerland, and Nephrology
Program, University of Chicago, Chicago, USA. THP has been de-
scribed either as promoter or inhibitor of the aggregation of calcium
oxalate monohydrate (COM) crystals. We have studied whether urinary
THP from normals (n THP) and idiopathic calcium oxalate stone
formers (sf THP) differ in their ability to inhibit crystal aggregation in
vitro, and, if so, what could be the mechanisms of reduced aggregation
inhibition. THP was purified from 24 hr urines of 6 healthy men and 6
male patients with severe idiopathic calcium oxalate nephrolithiasis
(>20 stones), and from the wife and 2 sons of one stone former. COM
crystal aggregation inhibition by 5 x iO M THP was measured at 200
mM NaCI, pH either 7.2 or 5.7. Surface zeta potential (ZP) of COM
crystals incubated with THPs was measured by a Zeta Meter. Intrinsic
viscosities of THP solutions (pH 5.7/200 mri NaCI) were determined
using a capillary viscometer, and axial Circular dichroism spectra (CD)
from one n THP and THPs from the family members of one stone
former were determined. COM crystal aggregation inhibition differed
between n THPs (72 7%, mean SEM) and sfTHPs (48 9%) only
at pH 5.7 (P < 0.05). There was no difference between negative ZPs
induced by n THPs and sf THPs, and the extent of crystal aggregation
inhibition was not correlated with the ZP. At pH 5.7/200 mrvi NaCI,
viscosity numbers sharply increased with decreasing [THP} below 90
mg/liter in 4/6 n THPs and 5/6 sfTHPs. With an additional 5mM
the viscosity increase with decreasing [THP] occurred in all 6 sfTHPs,
but none of then THPs. At pH 5.7/200 mst NaCI, increasing axial ratios
of THP molecules were linearly correlated with reduced COM crystal
aggregation inhibition (P < 0.001). CD measurements suggested more
beta-form of sf THP molecules, compared to n THP; THP molecules
from the 2 sons of one stone former were intermediate. Conclusions:
THPs isolated from individuals are heterogeneous COM crystal aggre-
gation inhibitors, and sf THPs inhibit less than n THPs at pH 5.7/200
mM NaCI. The formation of more elongated THP polymers (viscosity
increment) is linearly correlated with reduced COM crystal aggregation
inhibition. The abnormal viscosity increment with decreasing [THP] in
the presence of 5 mi Ca at pH 5.7/200 mi NaCI may indicate a
unique structural THP abnormality among idiopathic calcium oxalate
stone formers that seems to be inherited.
Cyclosporine should not be given on a "per kg" basis. H.A. Bock, V.
Kamber, B. Huser, J. Landmann, F. Brunner, G. Thiel, Abt. Nephrol-
ogie und Organtranspiantation, Kantonsspif a!, CH-4031 Base!, Swit-
zerland. The initial prescription of cyclosporine (CsA) is usually made
on a "per kg" basis, the underlying assumption being that heavier
patients require higher doses. We evaluated the rationale for this
concept by studying the relation of CsA dose to CsA blood level in all
164 kidney transplant recipients seen at our clinic during the first 4
months of 1988 (mean wt 68.9 kg, range 32.5 to 99.7; mean age 50.3,
range 13 to 71). CsA whole blood trough levels were measured using a
monoclonal RIA directed against unmetabolized CsA. Although the
relation of CsA level to CsA dose in patients with 3 or more data points(N = 65) was best fit by exponential curves, a linear regression with
zero-intercept was adequate in most. Therefore, the mean ratio of CsA
level and CsA dose (R:dose) was subsequently studied using data from
all 164 patients. R:dose was independent of age, sex, weight and height
but rose with time after transplantation (P < 0.05 by ANOVA):
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Time after
transplan-
tation <90 days 91 days—I yr 1—3 yr >3 yr
CsA level! 0.53 0.05 0.56 0.04 0.65 0.05 0.71 0.04
rng CsA,
X SEM
N 17 33 67 47
However, the ratio of CsA level to the per-kg dose (R:weight) increased
with weight,indicating that heavier patients have higher levels at the
same per-kg dose (P < 0.001 by ANOVA):
Weight
class kg <55 55—65 65—75 75—85 >85
CsA level! 30 37 47 53 51
(mg/kg
X SEM
CsA level/ 0.63 0.61 0.67 0.66 0.57
rng CsA,
X SEM
N 18 48 46 35 17
Individual CsA levels correlated better with absolute dose (N 1071, r
= 0.47) than with per-kg dose (r = 0.42). Based on these data we
conclude that prescribing CsA on a "per kg" basis 1) is unfounded and
2) carries the risk of overdosing obese and underdosing slim patients. A
dose of approximately 2 times the desired CsA level (mg and ng/ml
using the monoclonal RIA) should provide a reasonable initial estimate.
Serum parathyroid hormone concentration after intravenous
1,25(OH)2D3 treatment in hemodialysis patients. W. Probst, J.A.
Fischer, U, Binswanger, Nephrologische Station und Forschungslabor
für Calciumstoffwechsel, Dept. für Innere Medizin, Universitat Zurich,
Switzerland. Eleven patients on chronic hemodialysis treatment 3 times
weekly 2.5—4 hours using high-flux polysulfone filters F60 and acetate
dialysate with calcium of 1.5 mmol/liter received I g of I ,25(OH)2D3
iv. (Calciject, courtesy of ABBOTT Lab.) after each dialysis for 3
weeks. Phosphate binders were mainly CaCO3, in a few patients
supplemented by moderate amounts of Al(OH)3. Ionized calcium was
measured by ISE (AVL), normal values being 1.28 to 1.42 mmol/liter.
PTH was estimated by a N-terminal sensitive assay; normal values are
0.25 ng/ml. Results were as follows (mean SD; I before, 11 after 1,25
(OH)2D3):
I II
Ionized calcium before HD 1.19 0.12 1.17 0.14
Ionized calcium after HD 1.33 0.07 1.30 0.09
PTH before HD 1,39 0.71 1.38 0.69
PTH after HD 0.64 0.22 0.60 0.17
Phosphate before HD 1.85 0.48 2.18 0.43
A Corrected for hemoconcentration
No change of PTH concentrations and ionized calcium before hemodi-
alysis treatment could be documented after iv. 1,25 (OH)2D3 treatment.
Alterations of PTH concentrations during hemodialysis treatment were
similar and related to the increase in ionized calcium (r = 0.75, P <
0.01); in addition some removal of hormone through the dialysis filter
has to be considered.
Blood volume changes during high-flux short dialysis. T. Golia, U.
Binswanger, Nephrologische Station, Dept. für Innere Medizin, Uni-
versitatsspita/, Zurich, Switzerland. Blood volume changes (BVC)
obtained from hematocrit estimation before and after hemodialysis
treatment during 2.5 to 4 hours by polysulfone filters F60 using acetate
dialysate were related to changes of body weight (CBW). Three groups
of patients could be identified: (mean, range).
BVC CBW RR (s:systolic; d:diastolic)
% of mitt'a! value before after HD
I —5.2
—3.8 5: 155 21 129 20(N = 7) (4.9—6.0) (0.4—6.8) d: 87 8 82 13
II —12.8 —3.1 s: 137 16 119 20(N = 9) (6—22.2) (2.3—4.8) d: 84 8 72 13
III + 12.8
—1.5 5: 133 28 132 16(N = 5) (5.6—19.5) (0.2—2.7) d: 84 11 80 7
Group I and II patients exhibit smaller and larger % losses of volume
from intravascular space but a similar decrease in body weight. Group
III includes patients with gain of intravascular volume in spite of an
albeit small decrease in body weight. A high basal serum protein
concentration in this group might point towards relative initial dehydra-
tion and high colloid osmotic pressure; mobilization of extravascular
fluid as well as dialysate back flow in the filter seem to be involved in
blood volume expansion. From a clinical point of view, group land III
patients tolerate dialysis well, exhibiting stable blood pressure as
opposed to group II patients.
Transperitoneal ultrafiltration and lymphatic absorption in CAPD
patients: Utility for characterization of treatment efficiency. M. Hugen-
tobler, U. Binswanger. Nephrologische Station, Dept. für Innere
Medizin, Universitätsspital Zurich, Switzerland, According to pub-
lished techniques using equilibration-time curves, cumulative transcap-
illary ultrafiltration (CTU) with albumin as a marker and absorption of
albumin as measurement of lymphatic absorption (LA). 3 out of 12
patients showed striking abnormalities. 1) A 71-year-old male patient
suffering from amyloidosis affecting kidneys, intestine and heart, and
exhibiting hypoalbuminemia of 25 glliter, showed CTU of 1761 ml/4
hours and LA of 1088 ml/4 hours. 2) A 71-year-old male patient with
alcoholic liver disease and small amount of ascites before CAPD
showed CTU of 764 ml/4 hours, but LA of 882 ml/4 hours which
necessitated exchanges with higher glucose content. 3) Another male
56-year-old patient with repeated abdominal surgery and intraperitoneal
adhesions exhibited CTU of 255 ml/4 hours and LA 14 ml; solute
equilibration was slow. The study protocol proved to be very useful in
a substantial subgroup of patients in order to define abnormalities of
volume regulation in patients on CAPD and to decide on change of
treatment modality or switch to hemodialysis.
Protein adsorption on a cellulosic membrane selectively modifies leu-
kopenia and alterations of neutrophil functions during hemodialysis. P.
Neveceral, M. Markert, J.P. Waulers, Division de Néphro!ogie, Hop-
ital Universjtctire, Lausanne, Switzerland. Neutrophil dysfunctions
observed during dialysis on cellulosic membranes have been attributed
to systemic down-regulation of the cells by activated complement.
However, these defects were not observed after formalin re-use of
cellulosic membranes and required contact of the neutrophils with the
dialyzer membrane. To investigate the role of protein adsorption on the
interaction of neutrophils with cuprophane, a capillary dialyzer (CF
1511) was rinsed with saline and before clinical use primed at room
temperature for 10 mm with plasma, human albumin, or immunoglob-
ulins (Ig), and then rinsed again with saline before starting dialysis.
WBC count, neutrophil oxygen radical production and chemotaxis were
measured at the arterial (A) and venous (V) sites of the dialyzer at time
zero and 15 mm. Results are expressed as % of time zero values (mean
SEM of 3 to 5 experiments; ap < 0.05 vs. time zero):
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Priming
W
A
BC count
V
Ox
A
ygen radical
V
Chem
A
otaxis
V
Normal 16 3 19 3 17 16 31 8 81 5 52 2
Plasma 73 14 78 11 98 16 ill 16 99 7 105 8
Albumin 30 a 30 3 95 16 100 16 101 7 102 7
Ig 20 ia 23 2 99 30 90 18 — —
While total plasma proteins corrected both leukopenia and neutrophil
functional defects, albumin and immunoglobulins were able to prevent
neutrophil functional defects, but not leukopenia. Therefore, protein
adsorption appears to play a protective and essential role in membrane
biocompatibility.
Hypotension and renal impairment during infusion of atrial natriuretic
factor in liver cirrhosis with ascites. C. Ferrier, C. Beretta-Piccoli, P.
Weidmann, M. Gnadinger, S. Shaw, K. Suchecka-Rachon, H. Saxen-
hofer, Med. Poliklinik, University of Bern, Switzerland. Liver cirrhosis
is often associated with impaired renal sodium and water excretion.
Therefore, plasma levels of immunoreactive atrial natriuretic factor
(irANF) and effects of a-human ANF (a-hANF) infusion were investi-
gated in 7 patients (age SEM, 54 4 yr) with liver cirrhosis, ascites,
and a normal serum creatinine (<110 mol/liter). Under basal condi-
tions, supine blood pressure (BP) averaged 136 7/5 mm Hg. Plasma
irANF (by RIA, 124 33 pg/mI) was higher (P < 0.01) than in
age-matched normal subjects (47 5 pg/mI). Plasma renin activity
(PRA; 5.9 2,2 ng/mllhr), aldosterone (18 7 ng/dl) and norepineph-
rine (NE; 66 ng/dl) levels were also elevated compared to the
age-related normal range. a-hANF infusion for 60 mm at 0.036 g/
kg/mm decreased mean BP(—14%, P <0.05), increased PRA (+ 179%,
P < 0.05) and plasma NE (+ 24%, P < 0.05). Glomerular filtration rate
(GFR), effective renal plasma flow (ERPF) (by constant infusion
technique using 51Cr-EDTA and PAH, respectively), diuresis, and
natriuresis were not modified. A subsequent 60 mm infusion of a-hANF
at 0.067 zg/kg/min produced a marked fall in mean BP (—26%, P <
0.001), hemoconcentration (hematocrit +6%, P < 0.001) despite stable
body fluid balance, and a further increase in PRA (+ 350%, P < 0.005).
GFR and ERPF were severely reduced (—55%, and —56%, respec-
tively, P < 0.001), while diuresis and natriuresis were not modified.
Plasma aldosterone was unaltered during, but rose (+72%, P < 0.01)
after cessation of a-hANF infusion. Variations in natriuresis during
a-hANF infusion correlated positively with BP (r = 0.47, P < 0.01),
ERPF(r = 0.53, P <0.01) or GFR (r = 0.51, P <0.01). These findings
indicate that in patients with liver cirrhosis and ascites, plasma levels of
circulating irANF are increased. Infusion of a-hANP in pharmacolog-
ical dose can produce unwanted falls in BP, ERPF and GFR which, in
turn, preclude a therapeutically desired renal excretory response.
Follow-up study of pure vascular lesions. R. Donath, F. Chatelanat, L.
Humair, J-P. Bernhardt, E. Blanc, H. Favre, Department of Medicine
and Pathology, Hôpital Cantonal Universitaire de Genéve; Hôpital de
Ia Chaux-de-Fonds; Hopital de Porrentruy; Hopital de Sion, Switzer-
land. We have studied the follow-up of 14 pure vascular lesions of the
kidney (VL) identified by biopsy versus 33 proliferative glomerulone-
phritis with or without vascular lesions (GN), Arteriolar and arterial
lesions were each scored from 1 to 3 and summed up for each case. At
the time of the biopsy 35.7% of VL and 48.5% of GN had proteinuria
and hematuria, 42.8% of VL and 42.4% of GN proteinuria alone and
21.5% of VL and 9.1% ofGN hematuria alone. The mean age at biopsy
was 44.0 years (18 to 62) for VL and 43.9 (20 to 78) for GN. The mean
vascular score was 3.0 (Ito 5) for VL and 1.2(0 to 4) for GN. The mean
follow-up was 80 months (24 to 180) for VL and 53.5 (12 to 168) for GN.
HTAwas present in 85.7% of VL and 48.5% of GN (P <0.01) and was
well controlled on therapy during the entire follow-up in both groups.
There was no difference in the major vascular risk factors: urates 405.3
(VL) and 373.3 (GN) molIliter (p <0.5), cholesterol 5.76 (VL) and 6.43
(GN) mmol/liter (P < 0.2), triglycerides 1.98 (VL) and 2.05 (GN)
mmol/liter(P < 0.8), glucose 5.2 (VL) and 5.3 (GN) mmol/liter; 29% of
VL and 33% of GN were smokers (P < 0.7). Renal function deteriorated
(>50% increase in serum creatinine) in 4 VL patients (28.6%) versus 8
GN (24%). Out of them 3 VL (2 1.4%) and 5 GN (15%) started chronic
dialysis (P < 0.3). Two additional VL patients died of sudden death(15%). No death was reported in the GN group. These results suggest
that pure renal vascular lesions presenting clinically alike GN lesions
may be a specific pathological feature. Its prognosis is as serious as that
of proliferative glomerulonephritis and is independent of a satisfactory
control of the blood pressure.
Detection of small fiber lesions in uremic neuropathy by "Marstock"
thermotesting. M.J. Hilz, D. Claus, B. Neundorfer, V.P. Carvalho, J.
Braun. Neurologische und nephrologische, Klinik der Universitäi Er-
langen, Nürnberg, Federal Republic of Germany. The existence of
"small fiber" neuropathy in uremic patients as its own entity was first
discussed by Fruhstorfer et al (1976) who examined small nerve fibers
by thermal threshold measurement. To find out whether dysfunction of
large and small nerve fibers develops differently in patients hemodia-
lyzed due to chronic renal failure, 80 uremic patients were examined.
Forty patients (group A) had been hemodialyzed for less than 3 months.
Forty patients (group B) had already been on dialysis for more than
2-1/2 years. Clinical symptoms of neuropathy, impairment of nerve
conduction velocity (NCV) of median, ulnar, peroneal, tibial, and sural
nerves as a parameter of large fiber lesions, and impairment of thermal
threshold perception as a sign of small fiber dysfunction were all
measured. Using a "Marstock" thermotester, warm and cold percep-
tion thresholds were determined at the volar site of both wrists and
behind both medial malleoli. Some clinical signs of neuropathy were
seen in 10 patients of group A and in 17 patients of group B. test did
not show a statistical difference between the groups, whereas NCV was
impaired more frequently in group B (30 patients) than in group A (18
patient) ( = 6.302;P < 0.05). The average NCV was also slightly, but
significantly, lower in group B compared with group A (U-test: P <
0.05). In contrast, thermal thresholds were not more often raised in
group B (18 patients) than in group A (16 patients). Warm thresholds
improved on both malleoli in relation to the duration of chronic renal
failure (Spearman: P < 0.05). Comparison of mean thermal thresholds
in both groups also showed some improvement in group B. Conclusion:
While the function of large fibers slightly worsens during chronic renal
failure and hemodialysis, small fiber lesions do not progress but even
slightly improve. Considerations about different pathophysiological and
pathoanatomical lesions of small and large fibers in the course of
nephrogenic neuropathy might be inferred.
Evaluation of two monoclonal cyclosporine assays in the management of
kidney transplant patients. V. Kamber, H.A. Bock, B. Huser, J.
Landmann, M. Mihatsch, G. Thiel. The polyclonal RIA for cyclosporin
A (CsA-Poly) has recently been replaced with two monoclonal RIA's,
which recognize unmetabolized CsA (C5A-parent) and CsA metabolites
(CsA-Met). The 3 methods were compared prospectively by simulta-
neously assaying 1078 blood samples of all 164 patients seen during 4
months. There was an excellent correlation of CsA-parent and CsA-Met
with CsA-Poly (r = 0.85, P < 0.001 for both, CsA-Parent 0.40 x CsA
— Poly + 22). Of the 164 patients 31 had been transplanted at least 2
years earlier, were receiving CsA monotherapy and had Pcreat below
150 SM/liter. Their CsA-Parent levels ranged between 66 and 242 nglml.
A CsA-Parent trough level of 100 to 200 ng/ml appears to provide
adequate long-term immunosuppression. Whilst the parent CsA is
known for its immunosuppressive potency, certain metabolites could be
responsible for nephrotoxicity. However, the Cr was not significantly
higher in 42 blood samples with CsA-Met >1200 compared to 205
samples with CsA-Met <500 (Pcr 143 47 versus 121 36). In 42
transplant biopsies, a clear histological distinction could be made
between rejection (N = 29) and CsA toxicity (N = 13). The 2 groups
showed no significant differences in the CsA-Met as well as CsA-Parent
levels during the 10 days preceding the biopsy. Hence nephrotoxicity
does not seem to be related more to elevated CsA-Met than CsA-Parent
levels. Disproportionately elevated CsA-Met levels resulted from liver
dysfunction or drug interaction. In such cases underdosage of CsA
might be expected if CsA-Met levels were to be used for monitoring
immunosuppression with CsA. Conclusions: 1) CsA-Parent levels are
40% of the CsA-Poly levels, 2) Measuring CsA-Met does not provide
additional information regarding CsA-toxicity. 3) CsA-Met used alone
might overestimate immunosuppressive CsA-levels in patients with
liver dysfunction.
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Cyclosporine kinetics in renal transplant patients as assessed by HPLC
and RIA using monoclonal and polyclonat antibodies. B.M. Frey, R.F.
Speck, F.J. Frey. Medizinische Poliklinik, Universitãt Bern/Switzer-
land. Recently a RIA with a monoclonal antibody against cyclosporine
A (CsA) was marketed (Sandoz) and said to measure specifically CsA.
The purpose of the present investigation was to compare the areas
under the blood concentration vs. time curve of CsA (24 hrs), measured
by that monoclonal RIA with those obtained by HPLC or by the
commonly used polyclonal RIA in 10 renal transplant patients. The
mean blood concentrations determined by monoclonal RIA were 10 to
20% higher than those measured by HPLC, whereas the concentrations
assessed by polyclonal RIA were >100% higher than those determined
by HPLC. As a corollary, the pharmacokinetic parameters (clearance,
volume of distribution and systemic availability) differed when the
results from the three methods were compared. The RIA/HPLC con-
centration ratio of CsA was higher after oral than after i.v. dosing when
RIA measurements were performed by the polyclonal but not by the
monoclonal RIA. These ratios changed continuously during the first 12
hours after the administration when the polyclonal but not when the
monoclonal RIA was used. In conclusion, blood concentrations as-
sessed by the three methods are not identical and, when compared with
the polyclonal RIA, the monoclonal RIA exhibits three advantages: I)
much less cross reactivity with metabolites; 2) a constant RIA/HPLC
concentration ratio after the third hour after administration of CsA and;
3) a RIA/HPLC concentration ratio which is independent of the route of
administration.
Erythropoiesis and serum erythropoietin (EPO) levels before and
following renal transplantation. C. Keusch, A. Kurtz, J. Fehr, K.
Eckardt, C. Bauer, D. Frei, U. Binswanger, Dept. für Innere Medizin
und Physiologisches Institut der Universität Zurich, Switzerland. In
order to evaluate the improvement of erythropoiesis following renal
transplantation (RT) hematological parameters and serum EPO were
measured before and sequentially after RT in 50 cadaver RT recipients.
EPO was estimated using a sensitive radioimmunoassay. Mean hema-
tological values pretransplant were as follows: Hemoglobin 9.7 + 2.4
gldl; hematocrit (Hct) 29 + 8%; corrected reticulocytes count 15 + 8%0
and EPO 29 + 23(11 to 131) mU/mi. In the entire population studied 35
patients (pts) had inadequate low EPO levels for their degree of anemia.
In the whole population there was a significant positive exponential
correlation between EPO and Hct (r = 0.31, P < 0.05). Following
successful RT EPO increased to 45 + 31 mU/mI at one month (m) (P <
0.001) and then decreased to 25 + 18 mU/mI at 3 m (P < 0.001) and to
19 + 4 mU/mi at 9 m, respectively. Within the first posttransplant m
there was a fourfold increase in reticulocytes from 9 + 5/00 to 38 + 14
%0 (P < 0.001), followed by a slow decrease over the next several m.
In contrast Hct level rose more gradually from 28 + 7% to 44 + 6% at
9 m. In 25 of 36 pts with a functioning graft, who were followed for more
than 6 m anemia was corrected and 11 pts remained slightly anemic with
a mean hemoglobin level of 12 + 1.3 gldl and a Hct of 36 + 4%. EPO
levels were comparable in both subgroups of pts: 28 22 mU/mi and 26
19 mU/mi, respectively. Persistence of anemia in these pts was
probably due to the following causes: Impaired renal function (2 pts);
iron deficiency, amyloidosis, hemosiderosis and recurrent urinary tract
infection (each in one pt); in 4 pts no obvious reason could be detected.
Conclusions: Pretransplant serum EPO levels compared to Hct were
low Following RT EPO increased at one m and subsequentially
decreased indicating a normal feedback regulation between EPO and
Hct.
Prospective survey of transplant patients for CMV-infection by dif-
ferent methods. J.D. Auracher, W. Wunderli, R. Zbinden, D. Frei, G.
Keusch, U. Binswanger, Institute für Immunologie und Virologie der
Universitdt Zurich, Switzerland, Nephrologische Klinik, Universi-
tdlsspital Zurich, Switzerland. Twenty-five kidney-, II heart-, 4 liver-
and 3 bone marrow transplant patients were monitored weekly for
active CMV-infection. Virologically they were screened by direct
detection of immediate early antigen (IEAg) in isolated leucocytes and
by short cultivation of leucocytes and urine samples on cell cultures
(detection of early antigen, EAg). Simultaneously serum specimens
were tested for CMV-specific IgG and 1gM antibodies by ELISA.
Table: Donor/recipient status and incidence of CMV infection
Positive laboratory
CMV status of parameters for CMV(IEAg and/or EAg Clinical symptoms
Recipient Donor and/or 1gM) of CMV infection
+ — 9/13 2/9
+
—
—
+
—
+
9/12
11/13
4/5
4/9
4/11
4/4
From 25 CMV-IgG positive recipients 18 showed virus recurrence,
however, only 6 developed clinical symptoms, whereas from the 18
CMV-lgG negative recipients CMV was detected in 15 cases of which
8 developed clinical symptoms. The high number of CMV positive
samples from negative recipients may have resulted from the use of
CMV positive blood products. From the above, it may be concluded
that: in negative and positive recipients an active CMV infection is
often asymptomatic, namely in 7/15 and 12/18 cases respectively.
Negative recipients show a higher incidence of active CM V-infection
and an increased rate of clinical manifestation, therefore a positive
laboratory CMV parameter requires careful clinical surveillance in
order to start treatment without delay.
A matched-pair control study of diabetes mellitus after kidney trans-
plantation. A.v. Kiparski, D. Frei, G. Uhlschmid, 0. Keusch, F.
Largiader, U. Binswanger, Departments of Internal Medicine and
Surgery, University Hospital, Zurich, Switzerland. The incidence of
posttransplant diabetes mellitus (PTDM) was evaluated retrospectively
in 628 patients treated with azathioprine and prednisone and 273
patients receiving cyciosporine A in addition (triple therapy). Twenty-
four patients of the former and 8 patients of the latter group developed
PTDM requiring drug therapy (p: NS). Twenty patients showed hyper-
glycemia during the first 3 months after grafting, 12 patients after Ito 13
years. Thirty-two nondiabetic patients, matched for age, sex and
immunosuppressive protocol were used as case controls to identify
predisposing factors. Diabetics showed abnormal glucose tolerance in
13 of 31 cases as compared to 5 of 32 patients in controls (P < 0.05).
Four patients with PTDM had a history of chronic pancreatitis pretrans-
plant. HLA-B8, known to be associated with diabetes was significantly
more frequent in PTDM patients (9/29) than in controls (2/3 1; P <0.02).
Family history of diabetes, body weight and number of rejection
episodes were similar in both groups. Twelve of 32 patients developed
diabetes after prednisone pulse therapy and 11/32 patients had various
infections shortly before onset. In conclusion, PTDM seems to occur in
immunosuppressed kidney TPL-recipients sometimes predisposed by
abnormal glucose tolerance and/or history of chronic pancreatitis. The
incidence of PTDM was not increased in patients treated with cyclos-
porin A.
Recirculation (R) and effective creatinine and urea clearances during
high flux hemodialysis (HD). C. Zehnder, S. Koch, M. Spiess, Abteilung
Nephrologie, Kantonsspital, 5000 Aarau, Switzerland. High flux HD
with higher blood flow rates (Qb) is increasingly being used to shorten
treatment time. In order to evaluate the efficacy of increasing Qb, we
measured R, filter creatinine clearance (C) and urea clearance (Ce)
blood measurements) in 16 patients (pts) during a HD session with a
polysulfone filter (HF 60) at Qb of 300, 350 and 400 mI/mm and at a
constant dialysate flow. Ce,. and C were corrected by subtracting the
respective R rates. In 10 pts R was constant, whereas in the remaining
6 pts a marked rise in R was observed with increasing Qb. Corrected
Ccr and C were negatively influenced by high R rates (see table).
Angiography of these 6 pts revealed venous stenosis in 3 (2 subclavian,
I basilican vein). Three pts had a second choice access (2 goretex
grafts, 1 upper arm fistula), two with stenosis of the subclavian vein.
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Qb
mI/mm 300 350 400 P
R % 6.4 2.7a 8.3 1.9 8.5 2.6 NS
Ccrml/min 162.8 13.0 178.4 13.2 200.7 11.3 <0.001 N = 10
C mI/mm 204.6 8.6 217.7 7.9 234.5 14.1 <0.01
R % 11.8 8.Oa 16.9 8.9 21.0 8.0 <0.01
Ccr mI/mm 148.5 25.1 152.2 32.0 151.0 27.0 NS N = 6
C mI/mm 193.2 20.6 195.0 18.8 195.8 22.5 NS
Values are mean SD. All differences between the 2 groups were
statistically significant (P < 0.05) except a Conclusions: The favorable
effects of increasing Qb on dialyzer clearance occur only with intact a-v
fistulas. R testing provides valuable information about hemoaccess
integrity. Without correcting clearances for R the efficiency of HD may
be seriously overestimated.
Rebound of serum urea and 2-microglobulin concentration after high
flux hemodialysis. W. Probst, U. Binswanger, Nephrologische Station,
Dept. für Innere Medizin, Universitätsspital, Zurich, Switzerland.
Serum concentrations of urea and f32-microglobulin were monitored
after short time, 2.5 to 4 hours hemodialysis sessions, using polysulfon
filters F 60. Results were as follows (mean SD; N = 9).
Pre-
treatm.
Post-
treatm.
30 60 120
mm
Serum urea
mmol/liter
30.22 14.80 15.19 15.86 16.22
132-microglobulin
mg/liter
34.22 18.87 22.17 23.81 25.72
Serum urea rebound was small and should not influence calculation of
the dialysis index. However, for /32-microglobulin a mean rebound of
12% was found by extrapolation back to the end point of hemodialysis
treatment. This underestimation of the concentration posttreatment has
to be taken into account for calculation of distribution volume and
generation rate of this metabolite.
Effect of low potassium dialysate on the correction of hyperkalemia in
patients on long term hemodialysis. K. Vogt, B. Schletti, F. Amonn, B.
Lutold, Lindenhofspital and Institut Viollier, Bern, Switzerland. Cor-
rection of hyperkalemia remains an important aspect in patients on
hemodialysis (HD), especially with the use of erythropoietin (EPO).
Four stable patients on chronic HD (3 1/2 to 4 hr, 3 times a week; 2 on
EPO; mean age 47 yr, range 24 to 68 yr) were dialyzed during months
with dialysate containing 2 mEq/liter 2 K bath) and then at least 5 to 20
(mean 14) times with dialysate containing 1 mEq/liter (I k bath). No
patient had ischemic heart disease or was using digitalis. The HD were
done under standardized conditions using bicarbonate buffer and
polysulfone dialyzers. Holter ECG monitoring was performed during
the last HD studied with I K bath and the following 6 hours. All HD
were well tolerated. The patients had significantly lower predialysis and
postdialysis potassium serum levels on I K bath:
2Kbath lKbath
Pat pre post pre post
1 5.9(5.3—7.2) 4.3(3.8—4.8) 5.7(5.4—6.1) 4.0(3.7—4.1)
2 6.1(5.5—6.2) 4.1(3.6—4.6) 5.5(5.4—5.6) 3.4(3.3—3.7)
3 6.2(5.5—6.6) 4.2(3.5—4.5) 5.1(4.8—5.2) 3.6(3.4—3.8)4 6.5(6.1—6.8) 3.9(3.6—4.1) 5.5(5.2—6.1) 3.2(3.1—3.4)
No potentially dangerous arrhythmias were observed. Whereas the
patients 1 to 3 did only had isolated PAC's and PVC's, patient 4 with the
lowest postdialysis potassium of 3.2 mEq/liter had an increase of PVC's
from 19 in the first hour to 150 in the fourth hour of HD. Two hours after
dialysis the PVC's were down again to 20 per hour. We conclude that
the use of 1 K bath is effective in correcting hyperkalemia in HD
patients and may be used for a long-term period. However serial
measurements of serum potassium are mandatory to avoid serious
hypokalemia which may induce cardiac arrhythmias.
Immunogenicity of hepatitis B vaccines in dialysis patients. H. Jung-
bluth, M. Kuttelwascher, K. Záruba, Nierenstation, Stadtspital Waid
Zurich, Switzerland. One hundred and four of our dialysis patients have
been vaccinated against hepatitis B using a plasma derived vaccine
(H-B-Vax) or recombinant yeast derived vaccine (Gen H-B-Vax) from
Merck Sharp & Dohme (MSD). At least four to five doses of 40 ig of
the vaccine was administered intramuscularly at one month intervals.
Thirty (29%) of our dialysis patients (15 hemodialysis patients and 15
patients on CAPD) did not respond to hepatitis B vaccination. In these
nonresponders another trial with Institute Pasteur-vaccine (Hevac B
Pasteur) was started; Three to four doses of 5 g Pasteur vaccine were
administered intramuscularly in the deltoid muscle at one month
intervals. In this trial 16 of the nonresponders to MSD-vaccine (53%)
developed anti-HBs antibodies in a mean concentration of 393 mIU/ml
(range 18 to 1483 mlU/ml). The seroconversion rate was lower in CAPD
patients (7 patients = 47%) than in hemodialysis patients (9 patients =
60%). Four patients (13%) had already developed anti-HBs after the
first dose of Hevac B Pasteur vaccine, 10 patients (33%) after a series of
three vaccinations and another patient required four injections to
produce anti-HBs. Fourteen (47%) of the nonresponders to MSD
vaccine did not even respond to the Pasteur vaccine. This nonre-
sponders were longer on dialysis (mean 46 months, range 7 to 178
months), than the responders (mean 34 months, range 7 to 133 months).
Thus, in spite of a marked difference in HB5Ag content, the Pasteur
vaccine was more immunogenic than the MSD vaccine in a part of our
dialysis patients.
Human recombinant erythropoietin (r-huEPO) in anemic patients (pts)
on hemodialysis: Benefits and risks. C. Zehnder, Z. Gluck, C.
Descoeudres, A. Blumberg, Abteilung Nephrologie, Kantonsspital,
5000 Aarau, Medizinische Poliklinik, Inselspital, 3010 Bern, Switzer-
land. Eighteen pts were treated with r-huEPO 1 to 3 times/week during
10.7 3 months (mo); 4 of them received a kidney transplant, the
remaining 14 pts completed 12 mo of treatment. Hemoglobin (Hb) rose
from 7.0 0.7 to 11.0 1.1 g/dl (P < 0.001) in 12 mo with a
maintenance dose of 298 U/kg/week. The need for transfusions was
abolished. All 12 pts without iron overload required iron supplements.
In 2 pts an infection was followed by a fall in Hb despite increasing
r-huEPO dosage, but Hb rose when the pts recovered. Some compli-
cations related to the rise in Hb were observed: I) worsening of
hypertension (7/18) with hypertensive encephalopathy in 3; 2) arterio-
venous shunt thrombosis (3/18); 3) episodes of periarticular inflamma-
tiOn (4/18) due to calcified deposits with an elevated Ca/P product of 6.8;
4) hyperkalemia in 7 pts (6.9 0.3 mmol/liter). In 6 pts the influence of
rising Hb on filter creatinine clearance was studied during a 6 mo
period; an inverse correlation was found (r =
—0.72, P < 0.001). Better
control and treatment of hypertension, and modification of the dialysis
schedules reversed these complications as shown in the following data
(baseline before and 12 mo after r-huEPO): Arterial blood pressure
133.9 25/77.5 8.9 vs. 138.9 25.6/78.9 13.3 mm Hg (Ns),
potassium 5.4 0.4 vs. 5.6 1.0 mmol/liter (NS) and Ca/P 4.3 1.0 vs.
4.6 1.3 (Ns). Conclusions: Prolonged i.v. r-huEPO therapy of the
anemia of hemodialysis pts is effective and well tolerated. Complica-
tions due to increasing Hb concentrations may necessitate intensified
antihypertensive treatment and more efficient hemodialysis.
Risk and benefit of graft biopsy in renal transplantation under cyclos-
porin A. D. Kiss, J. Landmann, M. Mihatsch, B. Huser, F.P. Brunner,
G. Thiel, Dialysestation Kanlonsspital, Liestal, and Div. of Surgery,
Pathology, and Nephrology, University Hospital Basel, Switzerland.
To evaluate the benefit and risk of renal graft biopsies, we reviewed all
261 patients who received a kidney transplant under cyclosporin A
immunosuppression between November 1980 and June 1986. In 124 of(mean values and range in mEq/liter; N = 5 or > 5)
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the 261 patients 240 graft biopsies were performed (range I to 5). Graft
biopsies were performed for insufficient graft function in the early
posttransplant phase (N = 79), for graft function impairment in case of
primarily good graft function (N = 156) and for nephrotic proteinuria (N
= 5). The biopsy diagnoses were 103 x acute and chronic rejection, 90x
CsA toxicity, 8x acute tubular necrosis, 8x glomerulonephritis, 9x
different biopsy results and only 12 graft biopsies showed normal renal
tissue. The clinical picture was well explained in 214 cases. The
histological results led to therapeutical changes in 199 cases. Two
hundred and twenty-one out of 240 (92%) biopsies were performed
without any complications. The mean fall of hemoglobin was 0.8 0.87
g% (range 0.7.6 g%). Following graft biopsy 6 patients needed a blood
transfusion. There was only one irreversible complication: graft loss.
There were 19 reversible complications: tamponade of the urinary
bladder in 7 cases, symptomatic perirenal hematoma in 4 and 8 cases
with serious regional pain after graft biopsy. Conclusions: There is a
low incidence of serious irreversible graft biopsy complications (0.24%)
and a low incidence of reversible complications (8%). There was a high
incidence of therapeutic consequences (80%) and a high incidence of
graft function improvement (67%) following changed treatment. There-
fore, we propose a graft biopsy in any unclear graft function impair-
ment. Since cyclosporin A toxicity is clinically indistinguishable from
rejection, the histologic evaluation is mandatory.
Calcium carbonate for the treatment of hyperphosphatemia in chronic
HD patients. D. Kiss, Dialysestation Kantonsspital, 4410 Liestal,
Switzerland. The treatment of hyperphosphatemia in chronic hemodi-
alysis patients (HD pts) is usually performed by aluminium containing
phosphate binders. In the past years there has been increasing evidence
of serious complications by aluminium accumulation. We investigated a
new calcium carbonate preparation (CaCO3) with an HCI resistant
capsule that should prevent gastrointestinal side effects. Its phosphate
binding capacity was investigated in 17 chronic HD pts in comparison to
aluminum chloridehydroxide (AICh). Seventeen chronic HD pts under-
going routine HD (2 to 3x/week) treated with AICI for over 6 months
(period I) were changed to CaCO3 for 3 months (period II). The dose of
CaCO3 was adjusted every second week so that the serum phosphorus
levels were below 1.8 mmollliter. Calcitriol given to 13 of 17 pts during
period I was withheld during period II. In period I the mean dose of
AICh was 3.36 g/day (range 0.9 to 4.5 g/day) and in period II of CaCO3
4.96 g/day (range 1.5 to 6.0 g/day). The mean (± so) serum calcium level
was 2.58 0.11 mmol/liter in period I and 2.50 0.25 mmol/liter in
period II. The mean phosphorus level was 1.69 0.31 mmol/liter in
period land 1.71 0.33 mmollliter in period II. The serum aluminium
fell from 64.5 14.4 mcglliter to 28.5 17.5 mcglliter after 3 months.
In two pts we noted side effects. One patient developed hypercalcemia
of 3.03 mmol/liter and one patient stopped CaCO3 because of diarrhea.
Conclusions: The new HCI resistant preparation of CaCO3 is a potent
phosphate binder in chronic HD pts, without relevant side effects. The
serum calcium levels were well controlled as long as the dose did not
exceed 6 g/day. The serum aluminium levels dropped significantly.
Treatment of resistant hypertension following renal transplantation
with the angiotensin converting enzyme inhibitor (ACEi), enalapril (E):
Efficacy and effect on renal function. J. Schindler, G. Keusch, U.
Binswanger, Nephrologische Station, Dept. für Innere Medizin, Uni-
versitatsspital, Zurich, Switzerland. To evaluate the antihypertensive
efficacy and the effect on renal function of ACEi in the treatment of
hypertension resistant to conventional therapy following renal trans-
plantation, we retrospectively analyzed 28 hypertensive renal trans-
plant recipients treated with E. Prior to E therapy al patients (pts)
exhibited stable renal function for at least one month. Mean serum
creatinine was 188 95 (sn)mol/liter. Average systolic (sBP) and
diastolic blood pressures (dBP) determined from measurements ob-
tained in the seated position during the last 3 outpatient visits were 168
18 and 100 8 mm Hg, respectively. Administration of E in a daily
dosage of 13 6 (2.5 to 20) mg produced a significant decrease in sBP
and dBP. At the end of the treatment period of 10.3 10 (0.25 to 30)
months sBP and dBP were 141 25 and 89 9mm Hg (P < 0.001). In
23 out of 28 pts an adequate BP control of <160/95 mm Hg was
achieved. In 20 pts renal function remained stable during the entire
treatment period. Eight pts showed an increase in serum creatinine by
56 27% from 233 116 to 378 238 mol/liter (P < 0.001) 1 to 24
weeks after starting E. A renal angiography performed in all these pts
revealed a significant transplant renal artery stenosis (TRAS) in 5 cases
and diffusely narrowed intrarenal arteries, suggesting vascular rejection
in the remaining 3 pts. After correction of TRAS and discontinuation of
E, renal insufficiency was reversed in all cases. E was stopped in a
further 2 pts because of a transient ischemic attack in one pt and of
cough in another pt. In conclusion ACEis are effective in lowering
resistant BP following renal transplantation. Acute deterioration in
kidney function associated with ACEi therapy should rise the suspicion
of TRAS, but acute renal failure can also be due to diffuse narrowing of
intrarenal arteries.
Experience with prophylaxis of fungal peritonitis In patients on CAPD.
K. Záruba, J. Peters, H. Jungbluth, Nierenstation, Stadtspital Waid
Zurich, Switzerland. Fungal peritonitis is a serious complication of
continuous ambulatory peritoneal dialysis (CAPD) and is often associ-
ated with severe morbidity, CAPD 'drop-out" and rarely death. Most
episodes of fungal peritonitis occur during, or after a period of antibiotic
treatment because of different bacterial infections, usually of bacterial
peritonitis. From April 1979 to September 1988 a total of 109 patients
have been accepted in our CAPD program. Fourteen episodes of fungal
peritonitis occurred in these patients. After we have recognized that use
of antibiotics can predispose to fungal peritoneal infection in these
patients, a prophylaxis with 3 x 500 000 I.E. nystatin orally was
routinely started during every course of antibiotic treatment since
January 1983. In the first period (April 1979 to December 1982) 10
episodes of fungal peritonitis occurred during 42.8 patient years (0.234
episode per patient year); this is 10.5% of all peritonitis episodes(bacterial and fungal) in this interval. In the second period (January
1983 to September 1988), after nystatin prophylaxis had been intro-
duced routinely, only 4 episodes of fungal peritonitis occurred during
174.8 patient years (0.023 episode per patient year); this is 3.25% of all
peritonitis episodes in this second period. This difference is significant(P < 0.05). However, none of the four patients, who suffered from
fungal peritonitis in the second period had nystatin prophylaxis. Thus,
according to our experience, using the simple measure of prophylaxis
with antimycotics orally in every case of an antibiotic treatment, the
risk of fungal peritonitis can largely be eliminated in patients on CAPD.
Short dialysis—How much is enough? J.P. Wauters, S. Bercini
Pansiot, Division of Nephrology, University Hospital, Lausanne, Swit-
zerland. The prescription of dialysis therapy duration has been most
often decided empirically. During the last 15 years a progressive
shortening of the dialysis sessions has been generally applied under the
pressure of both patient's wishes and economic constraints. More
recently the advantages of long (3 x 5 hrs/week) or very long (2 X 12
hrs/week) schedules have been repeatedly advocated. In addition, a
KT/V ratio (weekly total urea clearance divided by urea distribution
volume) 1 has been recommended. Since 1976, all patients started on
HD in our unit have been treated following a 3 x 3 hrs/week schedule,
which was adapted individually by keeping midweek pre-dialysis blood
urea and creatinine levels at 28 mmol and 1200 mol/liter, respectively
and with an extraction ratio of at least 50%. This patient population was
largely unselected as demonstrated by: 1) an annual uptake of 20 to 36
patients which corresponds to approximately 70 new patients/million
inhabitants/year; 2)15% of our patients suffer from a systemic illness
(diabetes, SLE, . . .); 3) the mean age at start of therapy is 58 years.
Cumulative patient survival is 91% at 1 year, 76% at 5 years and 60% at
10 years. No worsening of anemia or uremic polyneuropathy was
observed. During the observation period, KT/V was generally between
0.7 and 0.9. Conclusion: in hemodialysis patients the long-term survival
attained with the 3 x 3 hrs/week schedule applied in our unit is
comparable or even superior to that of longer dialysis schedules. The
necessity of a KT/V ratio >1 appears questionable.
